MicroRNA-19a-3p Acts as an Oncogene in Gastric Cancer and Exerts the Effect by Targeting SMOC2.

MicroRNAs are reported to be involved in tumor development. This study aims to investigate the biological functions and molecular mechanisms of microRNA-19a-3p in gastric cancer cells. TCGA-based expression analysis and qRT-PCR assay illustrated that microRNA-19a-3p was overexpressed in gastric cancer.

MicroRNA-30c-2-3p targets STRIP2 to suppress malignant progression of gastric cancer cells.

MicroRNA plays a crucial part in genesis and development of gastric cancer (GC). We uncovered that microRNA-30c-2-3p was down-regulated in GC tissue and cell lines. Suppression of microRNA-30c-2-3p promoted progression of GC cells in vitro.

miR-133b Suppresses Invasion and Migration of Gastric Cancer Cells via the COL1A1/TGF-β Axis.

Objective: The study aimed to explore the mechanism of miR-133b regulating the invasion and migration of gastric cancer (GC) cells via the COL1A1/TGF-β axis.

Methods: The miRNA expression profiles of GC downloaded from TCGA database were subjected to differential analysis to determine the target miRNA of interest, and the target genes of the miRNA were predicted by bioinformatics. GSEA was used for gene enrichment analysis.

Clinicopathological and prognostic implications of arginase expression in hepatocellular carcinoma.

Background: To investigate the correlation of Arg-1 expression with clinicopathologic factors and prognosis of HCC patients, including recurrence and survival rate.

Methods: We examined the expression of Arg-1 in HCC by immunohistochemistry and studied its correlation with a series of clinicopathologic features and prognositic parameters of patients with HCC.

Results: We found patients with higher Arg-1 expression showed less aggressive features based on less portal vein invasion (chi2 = 10.

[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].

Objective: To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer.

Methods: The clinicopathological data of 118 patients with stage III colorectal cancer were studied retrospectively. The patients were assigned to receive either FOLFOX4 regimen (n = 76) or XELOX regimen (n = 42).

Concentration change of chemotherapeutic agents in plasma and tissue after intraarterial and intravenous injection.

Objective: To study the concentration change of chemotherapeutic agents in plasma and tissue after intraarterial and intravenous injection.

Methods: Ten mature female New Zealand rabbits were divided randomly into two groups. Fluorouracil, etopiside, and cisplatin were injected into the rabbits through the ear vein in one group and through the internal iliac artery in the other group.